High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors

Bone is a frequent metastatic site in advanced non-small cell lung cancer (aNSCLC), with up to 40  % of patients harboring bone metastases (BM) at diagnosis [1–3]. Bone targeted agents (BTA) – such as zoledronic acid and denosumab – demonstrated to prevent and/or delay the occurrence of skeletal related events (SRE) in patients with BM, with a manageable toxicity profile and a significan t benefit also in terms of quality of life [4–7].

Source: Lung Cancer - October 27, 2023 Category: Cancer & Oncology Authors: Sara Manglaviti, Marta Bini, Giulia Apollonio, Ernesto Zecca, Giulia Galli, Sabina Sangaletti, Alice Labianca, Elisa Sottotetti, Marta Brambilla, Mario Occhipinti, Claudia Proto, Arsela Prelaj, Diego Signorelli, Alessandro De Toma, Giuseppe Viscardi, Tere Source Type: research